Overview

A Study of TPD3310 in Patients With Advanced Malignant Tumors

Status:
NOT_YET_RECRUITING
Trial end date:
2029-03-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter, open phase I clinical study of dose escalation,cohort expansion study to evaluate the safety,tolerability,pharmacokinetics,pharmacodynamics, and preliminary efficacy of TPD3310 in patients withadvanced malignant solid tumors.
Phase:
PHASE1
Details
Lead Sponsor:
TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.